Polycationic dendrimers synergizes with gefitinib to overcome EGFREx19Del-driven resistance in non-small-cell lung cancer
-driven resistance. Overall, these findings highlight the translational potential of integrating membrane-targeted nanotherapeutics with EGFR-directed therapies to improve outcomes in NSCLC patients.
Authors
- Isabel Lemos (ORCID: https://orcid.org/0000-0002-0568-905X)
- José S. Ramalho (ORCID: https://orcid.org/0000-0002-1927-164X)
- Jacinta Serpa (ORCID: https://orcid.org/0000-0002-1548-5907)
- Duarte C. Barral (ORCID: https://orcid.org/0000-0001-8867-2407)
- Cindy Mendes (ORCID: https://orcid.org/0000-0002-8808-5082)
- Bruna Abreu
- Catarina Freitas‐Dias
- Filipe Gonçalves
- Bruna Sousa
- Adriana Cruz
- Rafael Gomes
- Vasco D. B. Bonifácio
Institutions
- Nova Medical (United States) (US)
- Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
- Institute for Biotechnology and Bioengineering (PT)
- Universidade Nova de Lisboa (PT)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1007/s12672-026-04934-0
- Primary Topic
- Dendrimers and Hyperbranched Polymers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação para a Ciência e a Tecnologia